The FDA has approved Journavx, a new type of painkiller that does not contain opioids, marking a significant advancement in pain management. Journavx targets moderate to severe acute pain and works by blocking pain signals in peripheral nerves, offering an alternative to addictive opioid-based medications.
The Food and Drug Administration ( FDA ) has granted approval for a novel type of pain medication, marking the first significant advancement in this field in over two decades. This groundbreaking painkiller, known as suzetrigine and marketed under the brand name Journavx , stands apart from conventional pain relievers by excluding opioids. Journavx targets moderate to severe acute pain, encompassing short-term discomfort arising from incidents like physical trauma or surgery.
Traditionally, doctors have relied on analgesics, many of which contain opioids, to manage this type of pain. Opioids function by activating specific receptors in the brain and body, effectively blocking pain signals. While they provide effective pain relief, opioids are notorious for their potential for addiction. Their ability to induce euphoria can reinforce drug use, leading to a high risk of dependence. This has contributed significantly to the ongoing opioid epidemic in the United States. In 2022, a staggering 76% of drug overdose fatalities involved opioids, encompassing both legally prescribed medications and illicit substances such as heroin, resulting in a tragic loss of 82,000 lives.Journavx, in contrast to opioids, does not produce a euphoric high. Instead, it functions by targeting peripheral pain-sensing neurons known as nociceptors. These neurons reside in the peripheral nervous system, separate from the brain, enabling pain relief without the addictive properties associated with opioids. Vertex Pharmaceuticals conducted extensive clinical trials involving 874 participants experiencing acute pain post-surgery. The trials employed a randomized, double-blind design, ensuring neither the patients nor the medical professionals were aware of who received the actual medication versus a placebo. Participants also had access to ibuprofen, a non-opioid pain reliever, as needed. The results demonstrated that patients administered Journavx experienced significantly greater pain reduction compared to those receiving the placebo. While Journavx is currently approved for adult use only, further research is needed to determine its safety and efficacy in children. Additionally, Vertex Pharmaceuticals has cautioned that Journavx may temporarily affect female fertility, potentially reducing the chances of conception during treatment. Patients with concerns about this aspect are advised to consult their physician before taking the drug
PAINKILLERS OPIOIDS FDA JOURNAVX PAIN MANAGEMENT ACUTE PAIN
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Approves Vertex's Non-Opioid Painkiller Journavx, Offering Hope for Millions Suffering from PainVertex Pharmaceuticals' non-opioid painkiller, Journavx, receives FDA approval, marking a significant milestone in the fight against the opioid epidemic. The drug offers a safe and effective alternative for pain relief without the risk of addiction.
Read more »
FDA Approves Vertex Pharmaceuticals' Non-Opioid Painkiller JournavxThe Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals' non-opioid painkiller, Journavx, marking a significant step forward in safer pain management. This milestone comes after years of efforts to develop alternatives to addictive opioids. Journavx works by blocking pain signals at their source, unlike opioids which directly impact the brain.
Read more »
FDA Approves New Nonopioid Pain Killer JournavxThe FDA has approved a new nonopioid painkiller, Journavx, for moderate to severe acute pain in adults. This could potentially reduce opioid prescriptions after surgery or provide an alternative for those who can't tolerate other pain medications.
Read more »
FDA Approves First Treatment for Dry Age-Related Macular DegenerationLumiThera's Valeda Light Delivery System shows significant promise in reducing vision loss and geographic atrophy in dry AMD patients.
Read more »
FDA Approves Sale of Nicotine Pouches For First TimeThe FDA has authorized the sale of nicotine pouches, a decision that has been met with both support and concern. The agency states that these pouches are less harmful than traditional tobacco products, but there are worries about their potential appeal to teenagers.
Read more »
FDA Approves First Nicotine Pouches for Sale, Citing Benefits for Adults Who Smoke or Use TobaccoThe FDA has authorized the sale of nicotine pouches, a fast-growing segment of the tobacco market, finding they meet the agency's requirements for harm reduction and minimal appeal to youth. Zyn, the first approved brand, contains fewer harmful ingredients than cigarettes and chewing tobacco and company data shows a substantial portion of adult smokers switched completely to Zyn. The decision comes despite warnings from antismoking groups about the product's potential to attract teens.
Read more »